[{"orgOrder":0,"company":"Disc medicine","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Disc medicine","amount2":0.20000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0.20000000000000001,"dosageForm":"Oral","sponsorNew":"Disc medicine \/ Disc Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Disc medicine \/ Disc Medicine"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Disc medicine \/ OrbiMed","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ OrbiMed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"DISC-0998","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Preclinical","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Gemini Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Merger","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Disc medicine \/ Gemini Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Gemini Therapeutics"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Mabwell","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"MWTX-001","moa":"","graph1":"Hematology","graph2":"IND Enabling","graph3":"Disc medicine","amount2":0.40999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Disc medicine \/ DISC MEDICINE","highestDevelopmentStatusID":"5","companyTruncated":"Disc medicine \/ DISC MEDICINE"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Mabwell","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"MWTX-003","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Disc medicine","amount2":0.41999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.41999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Mabwell","highestDevelopmentStatusID":"5","companyTruncated":"Disc medicine \/ Mabwell"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Disc medicine \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DISC-0974","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Disc medicine \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ National Institutes of Health"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Morgan Stanley"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Morgan Stanley"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.16,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Morgan Stanley"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bitopertin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Mabwell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DISC-3405","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Mabwell","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Mabwell"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DISC-3405","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"DISC-3405","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"DISC-0974","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Disc medicine \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Mabwell","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"9MW3011","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ DISC Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ DISC Medicine"},{"orgOrder":0,"company":"Disc medicine","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bitopertin","moa":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Disc medicine \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Bitopertin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Disc medicine \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Disc medicine \/ Hercules Capital"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bitopertin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Disc medicine \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Disc medicine
Details :
The proceeds will support the expected initiation of a confirmatory study of bitopertin in erythropoietic protoporphyria and a Phase 2 study of DISC-0974 in anemia of myelofibrosis.
Details :
DISC-1459 (bitopertin) is an investigational orally-administered inhibitor (GlyT1) that is designed to modulate heme biosynthesis. It is being evaluated for erythropoietic protoporphyria.
Details :
DISC-1459 (bitopertin) is an investigational orally-administered GlyT1 inhibitor being evaluated for erythropoietic protoporphyria treatment.
Details :
DISC-0974 is an investigational monoclonal antibody targeting a BMP-signaling co-receptor called hemojuvelin (HJV). It is being developed for anemia in non-dialysis dependent chronic kidney disease.
Details :
9MW3011 is an anti-TMPRSS6 antibody which can upregulate the level of hepcidin expressed by hepatocytes through specific binding. It is being evaluated for β-thalassemia and polycythemia vera.
Details :
DISC-3405 is an investigational, anti-TMPRSS6 (Matriptase-2) monoclonal antibody designed to increase hepcidin production and suppress serum iron. It is under development for polycythemia vera.
Details :
MWTX-003, also known as DISC-3405, is an investigational, anti-TMPRSS6 monoclonal antibody, which is investigated for the treatment of patients with polycythemia vera.
Details :
MWTX-003, also known as DISC-3405, is an investigational, anti-TMPRSS6 monoclonal antibody, which is investigated for the treatment of patients with polycythemia vera.
Details :
DISC-1459 (bitopertin) is an investigational, clinical-stage, orally-administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis, which is investigated for the treatment of diamond-blackfan anemia.
Details :
The proceeds will fund research and clinical development of Disc's candidates including, DISC-1459 (bitopertin), a first-in-class, oral small molecule inhibitor of glycine transporter 1, to treat erythropoietic porphyrias, a rare, genetically-driven hema...